Compare Old National Bancorp Common Stock (ONB) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Old National Bancorp Common Stock vs Sana Biotechnology Inc — how do they compare? Old National Bancorp Common Stock trades at $24.48 (market cap $9.42B), while Sana Biotechnology Inc trades at $2.33 (market cap $719.96M). The key difference: Old National Bancorp Common Stock is far larger — about 13.1× Sana Biotechnology Inc's market cap, and Old National Bancorp Common Stock pays a 2.36% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Old National Bancorp Common Stock for 0 Days and Sana Biotechnology Inc for 24 Days on average.
| ONB | SANA | |
|---|---|---|
Market Cap | $9.42B | $719.96M |
Volume | 4,606,260 | 4,901,517 |
Sector | Financials | Health |
52-Week High | $27.29 | $5.92 |
52-Week Low | $19.60 | $2.33 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $16.07B | $633.21M |
Dividend Yield | 2.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONB trades at $24.62, down 0.73% on the day, with a neutral technical outlook and key support at $24. The company shows strong fundamentals, with a P/E of 10.89 and net income margin of 31.39%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights upcoming Q3 earnings and positive institutional investment activity.
The outlook for ONB is positive, supported by robust earnings growth and a 'Buy' consensus from analysts with a $29.67 price target. Key risks include potential earnings volatility and macroeconomic pressures on the banking sector. Upside potential exists if the company continues its trend of exceeding earnings expectations.
SANA Biotechnology trades at $2.41, down 8.02% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company shows no revenue with substantial losses (-$244.17M net income in 2025) and negative cash flow, though analyst consensus remains strongly positive with 82% buy ratings. Recent investor conference presentations indicate active business development efforts.
The stock presents high-risk speculative potential with strong Wall Street support but faces fundamental challenges including no revenue generation and significant cash burn. Investment opportunity hinges on successful clinical developments, while risks include continued operational losses and potential dilution from financing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Old National Bancorp Common Stock
Old National Bancorp is the bank holding company for Old National Bank, providing consumer banking, commercial banking, wealth management, and capital markets services across Indiana, Kentucky, Michigan, Minnesota, and Wisconsin.
Read more on ONB →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
